H.R. 6509: SAFE Drugs Act of 2025

The SAFE Drugs Act of 2025 aims to enhance the regulation of compounding pharmacies and outsourcing facilities to ensure the safety and efficacy of compounded medications. Key provisions include: limiting pharmacies to compounding a drug that is essentially a copy of a commercially available product no more than 20 times per month; requiring reporting when compounding such drugs for out-of-state patients more than 20 times in a month; mandating inspections of large-scale outsourcing facilities before they begin compounding and at least every two years thereafter; and adjusting the base establishment fee for outsourcing facilities to adequately fund safety activities.

Supporters of the SAFE Drugs Act of 2025 argue that the bill strengthens oversight of compounding pharmacies, thereby enhancing patient safety by reducing the risk of exposure to unsafe or ineffective compounded medications. They believe that the reporting requirements and inspection mandates will lead to higher standards and accountability within the industry.

Critics contend that the SAFE Drugs Act of 2025 imposes burdensome regulations on compounding pharmacies, potentially limiting patient access to necessary compounded medications, especially during drug shortages. They argue that the restrictions on compounding copies of commercially available drugs and the increased reporting requirements could hinder the ability of pharmacies to meet patient needs effectively.

While there are no direct industry overlaps between the bill's subject matter and the sponsor's top donor industries, the lobbying activity surrounding the SAFE Drugs Act of 2025 raises some concerns. Notably, CEDIA contributed $120,000, and the Friends Committee on National Legislation contributed a significant $1,000,000. These contributions indicate a vested interest in the legislative outcomes related to drug safety and regulation. The undisclosed lobbying activities from various entities, including KNOA PHARMA LLC and SUR HOLDINGS, further complicate the transparency of potential influences on the bill. Voters should be aware that while direct conflicts are not evident, the substantial financial backing from organizations with interests in drug policy could create indirect pressures on the legislative process.

Organizations that lobbied on issues related to this bill's policy area.

Source: Senate Lobbying Disclosure Act (LDA) filings, 2026